The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype

被引:94
作者
Xiao, Yi [1 ]
Ye, Yin [1 ]
Yearsley, Kurtis [1 ]
Jones, Susie [1 ]
Barsky, Sanford H. [1 ]
机构
[1] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA
关键词
D O I
10.2353/ajpath.2008.071214
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Inflammatory breast carcinoma (IBC) is a particularly lethal form of breast cancer characterized by exaggerated lymphovascular invasion, which is a phenotype recapitulated in our human xenograft MARY-X. MARY-X generated spheroids in vitro that resemble the embryonal blastocyst. Because of the resemblance of the spheroids to the embryonal blastocyst and their resistance to traditional chemotherapy/radiotherapy, we hypothesized that the spheroids expressed a stem cell-like phenotype. MARY-X spheroids expressed embryonal stem cell markers including stellar, rex-1, nestin, H19, and potent transcriptional factors, oct-4, nanog, and sox-2, which are associated with stem cell self-renewal and developmental potential. Most importantly, MARY-X spheroids expressed a cancer stem cell profile characterized by CD44(+)/CD24(-/low), ALDH1, and most uniquely, CD133. A significant percentage of single cells of MARY-X exhibited distinct proliferative and morphogenic potencies in vitro. As few as 100 cells derived from single-cell clonogenic expansion were tumorigenic with recapitulation of the IBC phenotype. Prototype stem cell signaling pathways such as notch3 were active in MARY-X. The stem cell phenotype exhibited by MARY-X also was exhibited by the lymphovascular emboli of human IBC cases independent of their molecular subtype. This stem cell-like phenotype may contribute to the aggressive nature of IBC but also may lend itself to selective targeting.
引用
收藏
页码:561 / 574
页数:14
相关论文
共 49 条
[1]  
Abraham BK, 2005, CLIN CANCER RES, V11, P1154
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]  
Alpaugh ML, 1999, CANCER RES, V59, P5079
[4]   Relationship of sialyl-Lewisx/a underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma [J].
Alpaugh, ML ;
Tomlinson, JS ;
Ye, Y ;
Barsky, SH .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (02) :619-628
[5]   Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo [J].
Alpaugh, ML ;
Barsky, SH .
HUMAN GENE THERAPY, 2002, 13 (10) :1245-1258
[6]   Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma [J].
Alpaugh, ML ;
Tomlinson, JS ;
Kasraeian, S ;
Barsky, SH .
ONCOGENE, 2002, 21 (22) :3631-3643
[7]   Gene expression profiling identifies molecular subtypes of inflammatory breast cancer [J].
Bertucci, F ;
Finetti, P ;
Rougemont, J ;
Charafe-Jauffret, E ;
Cervera, N ;
Tarpin, C ;
Nguyen, C ;
Xerri, L ;
Houlgatte, M ;
Jacquemier, J ;
Viens, P ;
Birnbaum, D .
CANCER RESEARCH, 2005, 65 (06) :2170-2178
[8]   Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers [J].
Bertucci, Francois ;
Finetti, Pascal ;
Cervera, Nathalie ;
Charafe-Jauffret, Emmanuelle ;
Mamessier, Emilie ;
Adelaide, Jose ;
Debono, Stephane ;
Houvenaeghel, Gilles ;
Maraninchi, Dominique ;
Viens, Patrice ;
Charpin, Colette ;
Jacquemier, Jocelyne ;
Birnbaum, Daniel .
CANCER RESEARCH, 2006, 66 (09) :4636-4644
[9]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[10]   Core transcriptional regulatory circuitry in human embryonic stem cells [J].
Boyer, LA ;
Lee, TI ;
Cole, MF ;
Johnstone, SE ;
Levine, SS ;
Zucker, JR ;
Guenther, MG ;
Kumar, RM ;
Murray, HL ;
Jenner, RG ;
Gifford, DK ;
Melton, DA ;
Jaenisch, R ;
Young, RA .
CELL, 2005, 122 (06) :947-956